- Learn
Velox Peptides Guides
Educational resources for researchers working with HPLC-verified peptides - plain-English explainers, side-by-side compound comparisons, a research-terms glossary, and frequently asked questions. Everything you need to understand the science and the documentation behind each compound.
Last updated: 16 October 2026
For scientific reference only - not medical advice. All content is derived from peer-reviewed preclinical and clinical research. Summaries are provided for scientific reference, not medical advice, diagnosis, or treatment. All compounds are for in vitro research use only. Not for human or veterinary consumption.
Recently updated
FDA Receives Two Death Reports Tied to ‘Retatrutide’ Products
CBS reported on 13 Oct 2026 that FDA received two death reports after use of products sold as retatrutide. Causation is unproven and retatrutide remains unapproved.
Retatrutide FAERS Reports Explained
Public Citizen counted 26 FDA adverse-event reports mentioning retatrutide in early 2026. How the voluntary FAERS database works — and what its counts cannot show.
Retatrutide Ahead of Lilly’s Q3 Earnings
What Lilly has disclosed on retatrutide in 2026 and what is still open before its 29 Oct Q3 results: the Q1 2027 BLA plan, the pending Seventh Circuit ruling and access.
ANZCA Warning: GLP-1s, Peptides & Anaesthesia
The Australian and New Zealand College of Anaesthetists warned on 5 Oct 2026 that GLP-1 agonists and other peptides slow gastric emptying. What the notice says and what is unknown.
EloraTZP Phase 2b at EASD 2026
Lilly’s Phase 2b EloraTZP data: the amylin agonist eloralintide combined with tirzepatide vs tirzepatide 15 mg over 48 weeks in a type 2 diabetes population.
Victoria Liver Alert on ‘Retatrutide’-Labelled Products
Victoria reported six liver injuries linked to unapproved products labelled retatrutide; TGA testing found undeclared semaglutide in another — why verified COAs matter.
Week in Review: 4–10 Oct 2026
No new retatrutide readout, unpublished GLP-1 aging-clock data from ARDD and a second placebo-controlled BPC-157 trial registered — the week’s peptide research news.
Research Summary
GLP-1s & Biological-Age Clocks (ARDD 2026)
Novo Nordisk and Eli Lilly presented unpublished aging-clock analyses of semaglutide and tirzepatide at ARDD 2026. What was reported, and what it cannot show.
Retatrutide Evidence Status: October 2026
A dated map of the retatrutide record on 8 Oct 2026: TRIUMPH-1 in NEJM, TRIUMPH-2 in The Lancet, the Q1 2027 FDA filing plan and the still-pending Seventh Circuit appeal.
Trial Data
BPC-157 Rotator Cuff Pilot Trial (NCT07803250)
A newly registered 20-participant placebo-controlled pilot will study BPC-157 after arthroscopic rotator cuff repair — design, endpoints and why a pilot this size settles little.
TRIUMPH-1 Published in NEJM
Retatrutide’s TRIUMPH-1 Phase 3 trial (n=2,339) was published in the New England Journal of Medicine on 29 Sep 2026 — how its two estimands differ and what the paper reports.
Research Summary
BPC-157 Evidence Dispute: 2025–26 Papers
Journals disagree on BPC-157: a 2025 review, a rebuttal on angiogenesis and a 2026 AJSM primer on the limited clinical evidence. A third-party summary of the exchange.
GLP-1 Prescribing Trends, Ages 8–11 (Pediatrics)
A Pediatrics study of 3.5M US records reports GLP-1 prescribing in the 8–11 obesity cohort rose from 0.03% to 9.3% between 2019 and 2026. Data, limits and context.
Week in Review: 29 Sep–3 Oct 2026
TRIUMPH-2 in The Lancet, the undecided Seventh Circuit retatrutide appeal and the still-unwritten FDA peptide rule — the week’s peptide research news.
TRIUMPH-2 Lancet Safety & Tolerability Data
TRIUMPH-2’s Lancet paper reports adverse-event discontinuations of 3.8–11.6% across retatrutide arms vs 4.9% placebo, plus GI and dysesthesia rates.
TRIUMPH-2 Full Paper Published in The Lancet
The Lancet published the full TRIUMPH-2 paper on 30 Sep 2026, timed to EASD Milan: retatrutide achieved 20.8% body-weight loss and −1.6% A1C at 80 weeks in 1,152 adults with type 2 diabetes.
Week in Review: 22-28 Sep 2026
Seventh Circuit retatrutide hearing recap, FDA’s Empower ‘pretextual’ warning letter, the 17-peptide bioequivalence guidance deadline, and EASD 2026 opening in Milan.
DOJ Cites Franco v. Chobani in Retatrutide Case
Days before the 24 Sep hearing, DOJ filed a letter citing Franco v. Chobani — a new ruling on FDA deference — in Lilly’s retatrutide biologic-classification appeal.
FDA Calls Empower Pharmacy GLP-1s ‘Pretextual’
FDA’s 18 Sep 2026 warning letter brands Empower Pharmacy’s tirzepatide/niacinamide GLP-1 blends ‘pretextual’ copies of approved drugs — escalating the compounding crackdown.
FDA Revises Guidance for 17 Generic Peptides
FDA’s revised bioequivalence guidance for 17 generic peptides including tirzepatide and semaglutide closed for comment 28 Sep 2026 — the first step toward generic GLP-1 approvals.
7th Circuit Hears Retatrutide Biologic Case
The 7th Circuit heard Lilly’s retatrutide biologic-classification appeal on 24 Sept 2026 — a ruling is expected within weeks to months, before Lilly’s Q1 2027 BLA filing.
7th Circuit Hearing Preview: The Arguments
The Seventh Circuit heard Lilly’s retatrutide biologic-classification appeal on 24 Sept 2026 — what each side argued and the precedent at stake.
CagriSema Beats Tirzepatide in REIMAGINE 5
Novo’s CagriSema beat tirzepatide 12.4% vs 9.1% body-weight change in Phase 3 REIMAGINE 5 (21 Sep 2026); REDEFINE 9 also met its primary endpoint.
Foundayo Wins 1/3 of New GLP-1 Starts
Lilly’s CEO: Foundayo now takes 1/3 of new oral GLP-1 starts; Lilly wins 70% of 700k new Medicare GLP-1 patients since 1 Jul 2026.
Gray-Market Peptide Sellers and Crypto Payments
Chainalysis found crypto payments to gray-market peptide sellers hit a $100M/yr run rate in 2026 — what it means for verifying suppliers.
Week in Review: 16-21 Sep 2026
CBS’s LegitScript ad exposé, compounders fighting Lilly’s biologic bid, and a preview of the 24 Sep Seventh Circuit hearing.
Compounders vs Lilly: Biologic Classification Fight
A compounding-pharmacy trade group calls Lilly’s retatrutide biologic bid a ‘money grab’ ahead of the 24 Sep 2026 Seventh Circuit hearing.
LegitScript Seal Hid 80+ Retatrutide Sellers
CBS News (16 Sep 2026): 80+ retatrutide sellers used LegitScript certification to advertise the unapproved compound on Meta, Google and YouTube.
Retatrutide EASD 2026: TRIUMPH-2 Presentation
Lilly presented retatrutide’s TRIUMPH-2 data at EASD 2026 in Milan on 30 Sep; the full paper was published in The Lancet the same day.
Week in Review: 9-15 Sep 2026
UCLA’s 565-study peptide evidence review and Corbus’s oral CRB-913 data, a non-incretin rival to GLP-1-class compounds.
Research Summary
UCLA 565-Study Peptide Supplement Review
A 2026 AJSM review of 565 studies on BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu found human evidence for efficacy remains lacking.
CRB-913: A Non-Incretin Oral Compound
Corbus’s CRB-913, an oral CB1 inverse agonist, reports Phase 1b CANYON-1 topline data (14 Sep 2026) — a non-GLP-1 approach to metabolic research.
Retatrutide TRIUMPH Basket-Trial Design
Why Lilly nested sub-studies inside TRIUMPH-1, and how TRIUMPH-2/3/4 extend retatrutide’s Phase 3 programme across metabolic endpoints.
Retatrutide vs Mazdutide
Mazdutide, the first GLP-1/glucagon dual agonist approved anywhere (China, 27 June 2025), reports smaller GLORY-1/DREAMS trial losses than retatrutide's TRIUMPH data.
Tirzepatide vs Semaglutide: New Safety Data (2026)
A 2026 Clinical Obesity meta-analysis (41,381 patients) found tirzepatide cut more weight than semaglutide, but nearly doubled the serious-adverse-event rate.
Research Summary
Tesamorelin Meta-Analysis: Visceral Fat Data
A 2026 Obesity Research & Clinical Practice meta-analysis of 5 RCTs found tesamorelin cut visceral fat −27.71cm² and raised lean mass, with no glucose safety signal.
Week in Review: 2-8 Sep 2026
Tirzepatide's new CV nod, MHRA raids, a $30bn retatrutide forecast, FDA warning letters, and a BBC counterfeit exposé.
Foundayo vs Wegovy Pill: Oral GLP-1 Scripts Hit Highs
IQVIA data (4 Sep 2026): Lilly's Foundayo hit a record 44k weekly US scripts (+8%), Novo's Wegovy pill 181k (+3%) — both oral GLP-1s at new highs.
BBC: Organised Crime Behind Fake Retatrutide
BBC investigation (4-5 Sep 2026) found organised crime networks mass-producing counterfeit retatrutide, sold in the UK via gyms, salons and street sellers.
FDA Warning Letters Hit Five Online Peptide Sellers
FDA warned 5 sellers (24 Aug, posted 1 Sep 2026) for marketing retatrutide, tirzepatide & tesamorelin blends as unapproved new drugs.
Clarivate Names Retatrutide a Defining GLP-1 Drug
Clarivate’s Drugs to Watch 2026 projects retatrutide’s 2028 launch and $30.1bn in 2031 sales; analysts now estimate the compound could be worth over $10bn annually to Lilly.
MHRA's Illegal Retatrutide Manufacturing Raids
MHRA dismantled 3 illegal UK factories making counterfeit retatrutide/tirzepatide pens (Oct 2025-28 May 2026), seizing 14,000+ doses and making 2 arrests.
Tirzepatide Wins FDA Cardiovascular Indication
The FDA approved Mounjaro (tirzepatide) for cardiovascular risk reduction (28 Aug 2026), based on the randomised SURPASS-CVOT trial (NEJM) vs dulaglutide — noninferior, not superior.
Week in Review: 26 Aug-1 Sep 2026
Gray-market retatrutide underperforms trials, a sports-med peptide evidence review, MOTS-c and NAD+ mechanism studies, and a reassuring GLP-1 opioid-safety signal.
GLP-1 Drugs and Opioid Use Disorder: Safety Study
A Diabetes, Obesity and Metabolism target trial emulation (n=5,338) found GLP-1 receptor agonists did not raise psychiatric or GI risk in opioid use disorder, and lowered pancreatitis, insomnia and anxiety risk.
Research Summary
NAD+ Systematic Review: What 113 Studies Show
A 2026 Ageing Research Reviews analysis of 113 studies found oral NAD+ precursors reliably raise biomarkers, but no trial has tested injectable NAD+ itself for outcomes.
MOTS-c Study: Muscle Mitochondria & PGC-1α/AMPK
A Copenhagen mouse and human-microdialysis study found MOTS-c raises intrinsic mitochondrial efficiency and cuts ROS emission — but only when PGC-1α and AMPK signalling are intact.
Research Summary
Injectable Peptide Evidence Review 2026
A JBJS Reviews literature audit found GLP-1 agonists are the only injectable peptide class with reproducible RCT evidence — BPC-157, TB-500, CJC-1295, ipamorelin and tesamorelin remain investigational.
Gray-Market Retatrutide: Real-World Outcomes
An EHR cohort study found compounded/direct-to-consumer retatrutide users lost half the trial-level weight (7.2% vs 15.5%) yet kept a higher cardiovascular and neuropsychiatric symptom burden.
Week in Review: 21-25 Aug 2026
Retatrutide's biologic-classification appeal gets a 24 Sept court date, TRANSCEND-CKD's design paper lands, and Ireland's HPRA warns on black-market sales.
Retatrutide Meta-Analysis: Blood Pressure & Lipids
Independent meta-analysis (2026, High Blood Press Cardiovasc Prev) pooling RCTs found significant drops in BP, cholesterol and triglycerides, but no change in HDL-C.
HPRA Warns on Black-Market Retatrutide in Ireland
RTÉ reported (23 Aug 2026) a kidney-injury hospitalisation linked to gym-supplied retatrutide, as HPRA seizures of GLP-1-claiming products rose 30-fold in a year.
TRANSCEND-CKD: Retatrutide's Kidney Trial
Nephrology Dialysis Transplantation (2025): design and baseline data for a 146-patient Phase 2b trial testing retatrutide's effect on measured GFR in chronic kidney disease.
7th Circuit Oral Arguments Set for Retatrutide Case
The Seventh Circuit heard oral arguments on 24 Sep 2026 in Lilly v. Kennedy (retatrutide drug-vs-biologic classification); a written opinion is expected before Lilly’s Q1 2027 BLA filing.
Week in Review: 14-20 Aug 2026
Novo seeks an injunction against Lilly's GLP-1 ads, retatrutide's MASH data disappoints on fibrosis, AgRP neurons reframe how semaglutide works, and BPC-157 starts its first human trial.
Trial Data
BPC-157 Gets Its First Controlled Human Trial
Hudson Biotech's Phase 2 RCT (NCT07437547) is testing BPC-157 in 120 adults with MRI-confirmed hamstring strain — the first controlled human trial of BPC-157 ever to reach active recruitment.
New PNAS Study: AgRP Neurons and GLP-1 Body-Weight Change
Yale PNAS study (4 Aug 2026): sustained semaglutide treatment recruits AgRP hunger neurons rather than suppressing them, and the neurons are required for the drug's full weight-lowering effect in mice.
Retatrutide vs CagriSema
CagriSema missed non-inferiority vs tirzepatide in the REDEFINE-4 head-to-head trial (23 Feb 2026); how its REDEFINE data compares with retatrutide's TRIUMPH results.
Novo Files for Injunction Against Lilly's Ads
Novo Nordisk filed for an injunction (14 Aug 2026) to halt Lilly's Zepbound/Mounjaro ads — a federal court considers the motion 17 Aug 2026.
Retatrutide MASH Mouse & Hamster Study
New Obesity journal study (Briand et al., 2026): retatrutide cut liver triglycerides ~50% and body-weight 31% in MASH mice/hamsters, but not fibrosis or inflammation scores.
MHRA Approves Foundayo (Orforglipron)
MHRA approved Lilly's oral GLP-1 pill Foundayo (orforglipron) for UK body-weight change and type 2 diabetes on 10 Aug 2026 — first in Europe.
Week in Review: 7-13 Aug 2026
MHRA logs 216 GLP-1 deaths, retatrutide expanded access splits clinicians, Stanford flags the peptide evidence gap, and Lilly sues 6 black-market sellers.
Lilly Sues 6 Sellers of Black-Market Retatrutide
Eli Lilly filed six lawsuits (12 Aug 2026) over retatrutide mislabelled "research use only" — lab testing found wrong doses and even insulin in seized vials.
Stanford Medicine: The Peptide Craze Is Outpacing the Science
Stanford Medicine researchers (10 Aug 2026) warn peptide self-injection trends are outrunning human-safety evidence, citing contamination risk and testing gaps.
Retatrutide Expanded Access Splits Clinicians
Medscape reporting (5 Aug 2026) found doctors split on Lilly's retatrutide access programme — legitimate narrow pathway to some, request-overload risk to others.
MHRA Yellow Card: 216 Deaths Linked to GLP-1s
MHRA Yellow Card data (6 Aug 2026): 216 cumulative suspected-link death reports across Mounjaro, Wegovy & Saxenda — reports, not proven causation.
Retatrutide's Phase 3 Package Is Complete: Lilly Q2 Earnings
Lilly's Q2 2026 earnings (5 Aug) confirm retatrutide's Phase 3 package is complete; tirzepatide now outsells Novo's semaglutide by $10bn+.
Tirzepatide Cuts Cardiovascular Risk: BMJ Study
BMJ cohort study (5 Aug 2026, n=52,971) found tirzepatide initiators had a 32% lower relative risk of major cardiovascular events than sitagliptin initiators (HR 0.68).
Retatrutide's FDA Biologic Classification Fight
Lilly’s suit over whether retatrutide is a drug or biologic reached the Seventh Circuit; oral arguments were heard 24 Sep 2026, with a ruling expected before Lilly’s Q1 2027 BLA filing.
Week in Review: 2-6 Aug 2026
Lilly formalises retatrutide's expanded access programme amid reported doctor pushback, a new MC4R mouse study, and the Novo-Lilly ad lawsuit nears injunction.
Retatrutide Expanded Access Programme Opens
Lilly confirmed (3 Aug 2026) it will open a formal pre-approval expanded access programme for retatrutide with defined eligibility criteria and a ClinicalTrials.gov registration (NCT07629401).
Novo Nordisk Sues Eli Lilly Over GLP-1 Ads
Novo Nordisk sued Eli Lilly (21 Jul 2026) alleging Zepbound/Mounjaro ads omit newer high-dose Wegovy/Ozempic data; injunction motion due 17 Aug.
Week in Review: 28 Jul - 1 Aug 2026
CNN's mainstream take on the FDA peptide vote (31 Jul), deeper PCAC conflict-of-interest scrutiny, and a new UK ASA ad ruling vs Bolt Pharmacy.
Bolt Pharmacy's Fake Reviews: ASA Ruling
ASA (29 Jul 2026): Bolt Pharmacy's "UK Body-Weight Change Reviews" Facebook page was its own undisclosed ad for Wegovy & Mounjaro, not independent reviews.
PCAC Panel's Industry Ties: 8 Deciding Votes
AP/NBC (23 Jul 2026): 8 new PCAC voting members with peptide-industry ties voted as a bloc, supplying the entire winning margin behind the BPC-157, TB-500 & KPV compounding vote.
Why Did Lilly Delay Retatrutide's FDA Filing to 2027?
Eli Lilly confirmed (23 Jul 2026) retatrutide's BLA will now file in Q1 2027, citing manufacturing/quality-control data needs, alongside positive TRIUMPH-2/3 Phase 3 results.
Teens, TikTok & Gray-Market Peptides
Air Mail (27 Jul 2026), WSJ, RNZ and ScienceAlert report teens self-injecting unregulated gray-market retatrutide, melanotan and GHK-Cu after watching TikTok tutorials.
Peptide Research Week in Review: 20-27 July 2026
This week: retatrutide's TRIUMPH-2/3 topline results (23 Jul, up to 20.8%/22.6% body-weight change) and the FDA's PCAC vote clearing 6 of 7 compounding peptides (23-24 Jul) — and what's next before Feb 2027.
Retatrutide vs Aleniglipron (Oral GLP-1)
Structure Therapeutics' oral aleniglipron reported up to 16.2% body-weight change in Phase 2b (Nature Medicine, 5 Jun 2026); retatrutide's Phase 3 TRIUMPH-1 reported 28.3%.
PCAC Votes to Clear 6 of 7 Peptides, Rejects DSIP
FDA's PCAC voted 23-24 Jul 2026 to recommend BPC-157, TB-500, KPV, MOTS-c, Semax & Epitalon for compounding, overriding its own staff's advice; DSIP was the only rejection.
Retatrutide TRIUMPH-2 & TRIUMPH-3 Results
Lilly's 23 Jul 2026 topline data: TRIUMPH-2 reported up to 20.8% body-weight change (T2D population), TRIUMPH-3 up to 22.6% (CVD population) — TRIUMPH-3's MACE analysis remained inconclusive.
Retatrutide vs Zenagamtide (Amycretin)
Novo's zenagamtide (amycretin) posted 14.6% body-weight change in Phase 2b (ADA 2026); retatrutide's Phase 3 TRIUMPH-1 reported 28.3% at 80 weeks.
JAMA Study: Compounded GLP-1s Still Widely Sold
JAMA Health Forum (17 Jul 2026): 75 US clinics still sold compounded semaglutide/tirzepatide after FDA's shortage exemption ended 22 May 2025.
FDA Peptide Vote & the $30bn Telehealth Bet
Fortune (20 Jul 2026): Hims, Ro and other telehealth platforms are eyeing a ~$30bn peptide market ahead of the 23-24 Jul PCAC compounding vote.
Oral Wegovy Wins EU-Wide Approval
European Commission approved Novo Nordisk’s oral Wegovy pill (25mg semaglutide) on 15 Jul 2026 — first oral GLP-1 cleared EU-wide, ahead of Lilly’s Foundayo.
Retatrutide TRIUMPH-9: Dose-Escalation Trial
New ClinicalTrials.gov listing NCT07357415, informally tracked as TRIUMPH-9, tests dose-escalation regimens in ~600 participants (BMI ≥30, no type 2 diabetes).
Retatrutide TRIUMPH-2 & TRIUMPH-3: What's Left
TRIUMPH-1 (NEJM) and TRIUMPH-2 (The Lancet) are now peer-reviewed; TRIUMPH-3 is still topline-only. The ~10,000-patient cardiovascular outcomes trial (NCT06383390) remains the last major read-out.
Retatrutide Arrhythmia Signal: TRANSCEND-T2D-1
STAT News (6 Jun 2026): TRANSCEND-T2D-1 reported arrhythmia in 7 of 403 retatrutide participants vs 0 of 134 on placebo, plus 3 major CV events vs 0.
PCAC Hearing: BPC-157, TB-500 & 5 More Peptides (July 2026)
The FDA’s Pharmacy Compounding Advisory Committee meets 23–24 July 2026 to evaluate seven peptides for 503A bulk-compounding status. What researchers need to know.
Sandoz Files First Generic Tirzepatide ANDA
The FDA accepted Sandoz’s abbreviated applications for generic tirzepatide (Mounjaro & Zepbound) on 29 June 2026 — the first generic filing for a GIP/GLP-1 dual agonist.
TRIUMPH-1: Retatrutide 80-Week Phase 3 Data
The pivotal 80-week Phase 3 read-out (n=2,339): retatrutide 12 mg reported 28.3% mean body-weight change vs 2.2% with placebo. Full data presented at ADA 2026.
Retatrutide Dysesthesia: TRIUMPH-4 Safety Signal
TRIUMPH-4 (ADA 2026) reported dysesthesia in 20.9% on retatrutide 12 mg vs 0.7% placebo — a class-unique signal not seen with tirzepatide or semaglutide.
Oral Semaglutide: MHRA UK Approval (June 2026)
The MHRA approved oral semaglutide (Wegovy tablet) on 11 June 2026 — the first oral GLP-1 cleared in Europe. OASIS 4 trial reported 13.6% body-weight change at 64 weeks.
Peptide Research Landscape 2026
TRIUMPH-1, SYNCHRONIZE-1, orforglipron approval, oral semaglutide MHRA, FDA reclassification and the upcoming PCAC hearing — every major 2026 development in one hub.
Regulatory & News
FDA Receives Two Death Reports Tied to ‘Retatrutide’ Products
CBS reported on 13 Oct 2026 that FDA received two death reports after use of products sold as retatrutide. Causation is unproven and retatrutide remains unapproved.
Retatrutide FAERS Reports Explained
Public Citizen counted 26 FDA adverse-event reports mentioning retatrutide in early 2026. How the voluntary FAERS database works — and what its counts cannot show.
Retatrutide Ahead of Lilly’s Q3 Earnings
What Lilly has disclosed on retatrutide in 2026 and what is still open before its 29 Oct Q3 results: the Q1 2027 BLA plan, the pending Seventh Circuit ruling and access.
ANZCA Warning: GLP-1s, Peptides & Anaesthesia
The Australian and New Zealand College of Anaesthetists warned on 5 Oct 2026 that GLP-1 agonists and other peptides slow gastric emptying. What the notice says and what is unknown.
Victoria Liver Alert on ‘Retatrutide’-Labelled Products
Victoria reported six liver injuries linked to unapproved products labelled retatrutide; TGA testing found undeclared semaglutide in another — why verified COAs matter.
Week in Review: 4–10 Oct 2026
No new retatrutide readout, unpublished GLP-1 aging-clock data from ARDD and a second placebo-controlled BPC-157 trial registered — the week’s peptide research news.
Retatrutide Evidence Status: October 2026
A dated map of the retatrutide record on 8 Oct 2026: TRIUMPH-1 in NEJM, TRIUMPH-2 in The Lancet, the Q1 2027 FDA filing plan and the still-pending Seventh Circuit appeal.
Week in Review: 29 Sep–3 Oct 2026
TRIUMPH-2 in The Lancet, the undecided Seventh Circuit retatrutide appeal and the still-unwritten FDA peptide rule — the week’s peptide research news.
Week in Review: 22-28 Sep 2026
Seventh Circuit retatrutide hearing recap, FDA’s Empower ‘pretextual’ warning letter, the 17-peptide bioequivalence guidance deadline, and EASD 2026 opening in Milan.
DOJ Cites Franco v. Chobani in Retatrutide Case
Days before the 24 Sep hearing, DOJ filed a letter citing Franco v. Chobani — a new ruling on FDA deference — in Lilly’s retatrutide biologic-classification appeal.
FDA Calls Empower Pharmacy GLP-1s ‘Pretextual’
FDA’s 18 Sep 2026 warning letter brands Empower Pharmacy’s tirzepatide/niacinamide GLP-1 blends ‘pretextual’ copies of approved drugs — escalating the compounding crackdown.
FDA Revises Guidance for 17 Generic Peptides
FDA’s revised bioequivalence guidance for 17 generic peptides including tirzepatide and semaglutide closed for comment 28 Sep 2026 — the first step toward generic GLP-1 approvals.
7th Circuit Hears Retatrutide Biologic Case
The 7th Circuit heard Lilly’s retatrutide biologic-classification appeal on 24 Sept 2026 — a ruling is expected within weeks to months, before Lilly’s Q1 2027 BLA filing.
7th Circuit Hearing Preview: The Arguments
The Seventh Circuit heard Lilly’s retatrutide biologic-classification appeal on 24 Sept 2026 — what each side argued and the precedent at stake.
Foundayo Wins 1/3 of New GLP-1 Starts
Lilly’s CEO: Foundayo now takes 1/3 of new oral GLP-1 starts; Lilly wins 70% of 700k new Medicare GLP-1 patients since 1 Jul 2026.
Gray-Market Peptide Sellers and Crypto Payments
Chainalysis found crypto payments to gray-market peptide sellers hit a $100M/yr run rate in 2026 — what it means for verifying suppliers.
Week in Review: 16-21 Sep 2026
CBS’s LegitScript ad exposé, compounders fighting Lilly’s biologic bid, and a preview of the 24 Sep Seventh Circuit hearing.
Compounders vs Lilly: Biologic Classification Fight
A compounding-pharmacy trade group calls Lilly’s retatrutide biologic bid a ‘money grab’ ahead of the 24 Sep 2026 Seventh Circuit hearing.
LegitScript Seal Hid 80+ Retatrutide Sellers
CBS News (16 Sep 2026): 80+ retatrutide sellers used LegitScript certification to advertise the unapproved compound on Meta, Google and YouTube.
Week in Review: 9-15 Sep 2026
UCLA’s 565-study peptide evidence review and Corbus’s oral CRB-913 data, a non-incretin rival to GLP-1-class compounds.
Week in Review: 2-8 Sep 2026
Tirzepatide's new CV nod, MHRA raids, a $30bn retatrutide forecast, FDA warning letters, and a BBC counterfeit exposé.
Foundayo vs Wegovy Pill: Oral GLP-1 Scripts Hit Highs
IQVIA data (4 Sep 2026): Lilly's Foundayo hit a record 44k weekly US scripts (+8%), Novo's Wegovy pill 181k (+3%) — both oral GLP-1s at new highs.
BBC: Organised Crime Behind Fake Retatrutide
BBC investigation (4-5 Sep 2026) found organised crime networks mass-producing counterfeit retatrutide, sold in the UK via gyms, salons and street sellers.
FDA Warning Letters Hit Five Online Peptide Sellers
FDA warned 5 sellers (24 Aug, posted 1 Sep 2026) for marketing retatrutide, tirzepatide & tesamorelin blends as unapproved new drugs.
Clarivate Names Retatrutide a Defining GLP-1 Drug
Clarivate’s Drugs to Watch 2026 projects retatrutide’s 2028 launch and $30.1bn in 2031 sales; analysts now estimate the compound could be worth over $10bn annually to Lilly.
MHRA's Illegal Retatrutide Manufacturing Raids
MHRA dismantled 3 illegal UK factories making counterfeit retatrutide/tirzepatide pens (Oct 2025-28 May 2026), seizing 14,000+ doses and making 2 arrests.
Tirzepatide Wins FDA Cardiovascular Indication
The FDA approved Mounjaro (tirzepatide) for cardiovascular risk reduction (28 Aug 2026), based on the randomised SURPASS-CVOT trial (NEJM) vs dulaglutide — noninferior, not superior.
Gray-Market Retatrutide: Real-World Outcomes
An EHR cohort study found compounded/direct-to-consumer retatrutide users lost half the trial-level weight (7.2% vs 15.5%) yet kept a higher cardiovascular and neuropsychiatric symptom burden.
Week in Review: 21-25 Aug 2026
Retatrutide's biologic-classification appeal gets a 24 Sept court date, TRANSCEND-CKD's design paper lands, and Ireland's HPRA warns on black-market sales.
HPRA Warns on Black-Market Retatrutide in Ireland
RTÉ reported (23 Aug 2026) a kidney-injury hospitalisation linked to gym-supplied retatrutide, as HPRA seizures of GLP-1-claiming products rose 30-fold in a year.
7th Circuit Oral Arguments Set for Retatrutide Case
The Seventh Circuit heard oral arguments on 24 Sep 2026 in Lilly v. Kennedy (retatrutide drug-vs-biologic classification); a written opinion is expected before Lilly’s Q1 2027 BLA filing.
Week in Review: 14-20 Aug 2026
Novo seeks an injunction against Lilly's GLP-1 ads, retatrutide's MASH data disappoints on fibrosis, AgRP neurons reframe how semaglutide works, and BPC-157 starts its first human trial.
Novo Files for Injunction Against Lilly's Ads
Novo Nordisk filed for an injunction (14 Aug 2026) to halt Lilly's Zepbound/Mounjaro ads — a federal court considers the motion 17 Aug 2026.
MHRA Approves Foundayo (Orforglipron)
MHRA approved Lilly's oral GLP-1 pill Foundayo (orforglipron) for UK body-weight change and type 2 diabetes on 10 Aug 2026 — first in Europe.
Week in Review: 7-13 Aug 2026
MHRA logs 216 GLP-1 deaths, retatrutide expanded access splits clinicians, Stanford flags the peptide evidence gap, and Lilly sues 6 black-market sellers.
Lilly Sues 6 Sellers of Black-Market Retatrutide
Eli Lilly filed six lawsuits (12 Aug 2026) over retatrutide mislabelled "research use only" — lab testing found wrong doses and even insulin in seized vials.
Stanford Medicine: The Peptide Craze Is Outpacing the Science
Stanford Medicine researchers (10 Aug 2026) warn peptide self-injection trends are outrunning human-safety evidence, citing contamination risk and testing gaps.
Retatrutide Expanded Access Splits Clinicians
Medscape reporting (5 Aug 2026) found doctors split on Lilly's retatrutide access programme — legitimate narrow pathway to some, request-overload risk to others.
MHRA Yellow Card: 216 Deaths Linked to GLP-1s
MHRA Yellow Card data (6 Aug 2026): 216 cumulative suspected-link death reports across Mounjaro, Wegovy & Saxenda — reports, not proven causation.
Retatrutide's Phase 3 Package Is Complete: Lilly Q2 Earnings
Lilly's Q2 2026 earnings (5 Aug) confirm retatrutide's Phase 3 package is complete; tirzepatide now outsells Novo's semaglutide by $10bn+.
Retatrutide's FDA Biologic Classification Fight
Lilly’s suit over whether retatrutide is a drug or biologic reached the Seventh Circuit; oral arguments were heard 24 Sep 2026, with a ruling expected before Lilly’s Q1 2027 BLA filing.
Week in Review: 2-6 Aug 2026
Lilly formalises retatrutide's expanded access programme amid reported doctor pushback, a new MC4R mouse study, and the Novo-Lilly ad lawsuit nears injunction.
FDA 503B Comment Period Closes: What's Next
FDA's public comment window on excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list closed 30 Jul 2026 — no ruling yet.
Novo Nordisk Sues Eli Lilly Over GLP-1 Ads
Novo Nordisk sued Eli Lilly (21 Jul 2026) alleging Zepbound/Mounjaro ads omit newer high-dose Wegovy/Ozempic data; injunction motion due 17 Aug.
Week in Review: 28 Jul - 1 Aug 2026
CNN's mainstream take on the FDA peptide vote (31 Jul), deeper PCAC conflict-of-interest scrutiny, and a new UK ASA ad ruling vs Bolt Pharmacy.
Bolt Pharmacy's Fake Reviews: ASA Ruling
ASA (29 Jul 2026): Bolt Pharmacy's "UK Body-Weight Change Reviews" Facebook page was its own undisclosed ad for Wegovy & Mounjaro, not independent reviews.
PCAC Panel's Industry Ties: 8 Deciding Votes
AP/NBC (23 Jul 2026): 8 new PCAC voting members with peptide-industry ties voted as a bloc, supplying the entire winning margin behind the BPC-157, TB-500 & KPV compounding vote.
Why Did Lilly Delay Retatrutide's FDA Filing to 2027?
Eli Lilly confirmed (23 Jul 2026) retatrutide's BLA will now file in Q1 2027, citing manufacturing/quality-control data needs, alongside positive TRIUMPH-2/3 Phase 3 results.
Teens, TikTok & Gray-Market Peptides
Air Mail (27 Jul 2026), WSJ, RNZ and ScienceAlert report teens self-injecting unregulated gray-market retatrutide, melanotan and GHK-Cu after watching TikTok tutorials.
Peptide Research Week in Review: 20-27 July 2026
This week: retatrutide's TRIUMPH-2/3 topline results (23 Jul) and the FDA's PCAC vote clearing 6 of 7 compounding peptides (23-24 Jul) — and what's next before Feb 2027.
PCAC Votes to Clear 6 of 7 Peptides, Rejects DSIP
FDA's PCAC voted 23-24 Jul 2026 to recommend BPC-157, TB-500, KPV, MOTS-c, Semax & Epitalon for compounding, overriding its own staff's advice; DSIP was the only rejection.
JAMA Study: Compounded GLP-1s Still Widely Sold
JAMA Health Forum (17 Jul 2026): a secret-shopper study found 75 US clinics still selling compounded semaglutide/tirzepatide after the FDA's 22 May 2025 compounding cutoff.
FDA Peptide Vote & the $30bn Telehealth Bet
Fortune (20 Jul 2026): telehealth firms are eyeing a ~$30bn peptide market ahead of the 23-24 Jul PCAC vote; Canaccord raised Hims & Hers’ target to $40.
MHRA vs Tesco Pharmacy: Weight-Loss Ad Enforcement
MHRA acted against Tesco Pharmacy's body-weight-change ads (7 Jul 2026) — the first named outcome of its June ad crackdown. An NPA survey found 97% of pharmacies fear a counterfeit surge.
Oral Wegovy Wins EU-Wide Approval
European Commission approved Novo Nordisk’s oral Wegovy pill (25mg semaglutide) on 15 Jul 2026 — first oral GLP-1 cleared EU-wide, ahead of Lilly’s Foundayo.
FDA Peptide Reclassification 2026
Twelve peptides including BPC-157, TB-500 and Semax removed from FDA 503A Category 2 in April 2026. Full list, timeline and context for researchers.
FDA PCAC 2026: BPC-157, TB-500 & 5 More
The PCAC meets 23–24 July 2026 to vote on 503A Category 1 status for seven peptides. Public comments closed 9 July. Guide to each compound’s evidence dossier.
FDA Flags Peptide Evidence Gaps (2026 Briefing)
The FDA’s 29 June 2026 briefing documents found no human data for TB-500 and KPV, and insufficient evidence for BPC-157, ahead of the PCAC vote.
PCAC 2026: Patient Safety Groups vs Compounders
Partnership for Safe Medicines urged the FDA to reject all 7 peptides; the Alliance for Pharmacy Compounding wants a regulated “third way” before the 23-24 Jul vote.
Retatrutide FDA Approval Timeline 2026–2028
Lilly now plans its FDA filing for Q1 2027, after TRIUMPH-1 (NEJM) and TRIUMPH-2 (The Lancet) were published. Phase 3 milestones, MHRA UK outlook and research-use context.
Retatrutide FDA Expanded Access (2026)
In June 2026 the FDA granted compassionate-use expanded access to retatrutide for one patient outside Phase 3 trials. What it means for the approval timeline.
FDA Curbs Bulk Tirzepatide & Semaglutide Compounding
FDA (30 Apr 2026) proposed excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list. Public comments close 30 July 2026.
Canada Approves Generic Semaglutide: Sevmia
Health Canada approved Sevmia (Apotex) on 29 June 2026 — the first generic semaglutide product referencing the Wegovy brand authorisation.
GHK-Cu & Melanotan-II: PCAC Date Set for Feb 2027
FDA set a February 2027 PCAC date for GHK-Cu (injectable) and Melanotan-II compounding review — the second batch after July 2026’s seven-peptide hearing.
UK GLP-1 Advertising Crackdown: MHRA & ASA (2026)
MHRA, ASA and GPhC jointly warned UK sellers (18 June 2026) against advertising unlicensed body-weight-change pipeline drugs and unregulated waiting lists.
BPC-157 Grey Market: FDA Compounding Curbs Backfire
NPR (8 Jul 2026): US compounding limits pushed BPC-157, TB-500 and MOTS-c buyers to unvetted overseas sellers ahead of the 23–24 Jul PCAC vote.
2026 Conference & Trial Data
EloraTZP Phase 2b at EASD 2026
Lilly’s Phase 2b EloraTZP data: the amylin agonist eloralintide combined with tirzepatide vs tirzepatide 15 mg over 48 weeks in a type 2 diabetes population.
Research Summary
GLP-1s & Biological-Age Clocks (ARDD 2026)
Novo Nordisk and Eli Lilly presented unpublished aging-clock analyses of semaglutide and tirzepatide at ARDD 2026. What was reported, and what it cannot show.
Trial Data
BPC-157 Rotator Cuff Pilot Trial (NCT07803250)
A newly registered 20-participant placebo-controlled pilot will study BPC-157 after arthroscopic rotator cuff repair — design, endpoints and why a pilot this size settles little.
TRIUMPH-1 Published in NEJM
Retatrutide’s TRIUMPH-1 Phase 3 trial (n=2,339) was published in the New England Journal of Medicine on 29 Sep 2026 — how its two estimands differ and what the paper reports.
TRIUMPH-2 Lancet Safety & Tolerability Data
TRIUMPH-2’s Lancet paper reports adverse-event discontinuations of 3.8–11.6% across retatrutide arms vs 4.9% placebo, plus GI and dysesthesia rates.
TRIUMPH-2 Full Paper Published in The Lancet
The Lancet published the full TRIUMPH-2 paper on 30 Sep 2026, timed to EASD Milan: retatrutide achieved 20.8% body-weight loss and −1.6% A1C at 80 weeks in 1,152 adults with type 2 diabetes.
CagriSema Beats Tirzepatide in REIMAGINE 5
Novo’s CagriSema beat tirzepatide 12.4% vs 9.1% body-weight change in Phase 3 REIMAGINE 5 (21 Sep 2026); REDEFINE 9 also met its primary endpoint.
Retatrutide EASD 2026: TRIUMPH-2 Presentation
Lilly presented retatrutide’s TRIUMPH-2 data at EASD 2026 in Milan on 30 Sep; the full paper was published in The Lancet the same day.
CRB-913: A Non-Incretin Oral Compound
Corbus’s CRB-913, an oral CB1 inverse agonist, reports Phase 1b CANYON-1 topline data (14 Sep 2026) — a non-GLP-1 approach to metabolic research.
Retatrutide vs Mazdutide
Mazdutide, the first GLP-1/glucagon dual agonist approved anywhere (China, 27 June 2025), reports smaller GLORY-1/DREAMS trial losses than retatrutide's TRIUMPH data.
Tirzepatide vs Semaglutide: New Safety Data (2026)
A 2026 Clinical Obesity meta-analysis (41,381 patients) found tirzepatide cut more weight than semaglutide, but nearly doubled the serious-adverse-event rate.
Research Summary
Tesamorelin Meta-Analysis: Visceral Fat Data
A 2026 Obesity Research & Clinical Practice meta-analysis of 5 RCTs found tesamorelin cut visceral fat −27.71cm² and raised lean mass, with no glucose safety signal.
Week in Review: 2-8 Sep 2026
Tirzepatide's new CV nod, MHRA raids, a $30bn retatrutide forecast, FDA warning letters, and a BBC counterfeit exposé.
Week in Review: 26 Aug-1 Sep 2026
Gray-market retatrutide underperforms trials, a sports-med peptide evidence review, MOTS-c and NAD+ mechanism studies, and a reassuring GLP-1 opioid-safety signal.
GLP-1 Drugs and Opioid Use Disorder: Safety Study
A Diabetes, Obesity and Metabolism target trial emulation (n=5,338) found GLP-1 receptor agonists did not raise psychiatric or GI risk in opioid use disorder, and lowered pancreatitis, insomnia and anxiety risk.
Research Summary
NAD+ Systematic Review: What 113 Studies Show
A 2026 Ageing Research Reviews analysis of 113 studies found oral NAD+ precursors reliably raise biomarkers, but no trial has tested injectable NAD+ itself for outcomes.
MOTS-c Study: Muscle Mitochondria & PGC-1α/AMPK
A Copenhagen mouse and human-microdialysis study found MOTS-c raises intrinsic mitochondrial efficiency and cuts ROS emission — but only when PGC-1α and AMPK signalling are intact.
Research Summary
Injectable Peptide Evidence Review 2026
A JBJS Reviews literature audit found GLP-1 agonists are the only injectable peptide class with reproducible RCT evidence — BPC-157, TB-500, CJC-1295, ipamorelin and tesamorelin remain investigational.
Retatrutide Meta-Analysis: Blood Pressure & Lipids
Independent meta-analysis (2026, High Blood Press Cardiovasc Prev) pooling RCTs found significant drops in BP, cholesterol and triglycerides, but no change in HDL-C.
Trial Data
BPC-157 Gets Its First Controlled Human Trial
Hudson Biotech's Phase 2 RCT (NCT07437547) is testing BPC-157 in 120 adults with MRI-confirmed hamstring strain — the first controlled human trial of BPC-157 ever to reach active recruitment.
New PNAS Study: AgRP Neurons and GLP-1 Body-Weight Change
Yale PNAS study (4 Aug 2026): sustained semaglutide treatment recruits AgRP hunger neurons rather than suppressing them, and the neurons are required for the drug's full weight-lowering effect in mice.
Retatrutide vs CagriSema
CagriSema missed non-inferiority vs tirzepatide in the REDEFINE-4 head-to-head trial (23 Feb 2026); how its REDEFINE data compares with retatrutide's TRIUMPH results.
Tirzepatide Cuts Cardiovascular Risk: BMJ Study
BMJ cohort study (5 Aug 2026, n=52,971) found tirzepatide initiators had a 32% lower relative risk of major cardiovascular events than sitagliptin initiators (HR 0.68).
Retatrutide MASH Mouse & Hamster Study
Obesity journal study (Briand et al., 2026): retatrutide cut liver triglycerides ~50% and body-weight 31% in diet-induced MASH mice/hamsters, but not fibrosis or inflammation histology scores.
MC4R-Deficient Mouse Study: Retatrutide vs Tirzepatide
Feb 2026 Int J Obes preclinical study compared semaglutide (19.7%), tirzepatide (31.6%) and retatrutide (24.1%) body-weight change in MC4R-knockout mice over 21 days. Rodent data only.
Retatrutide TRIUMPH-9: Dose-Escalation Trial
NCT07357415 tests different dose-escalation regimens in ~600 participants (BMI ≥30, no T2D) — a design question, not a new maintenance dose.
Retatrutide TRIUMPH-2 & TRIUMPH-3: What's Left
TRIUMPH-1 (NEJM) and TRIUMPH-2 (The Lancet) are now peer-reviewed; TRIUMPH-3 is still topline-only. The ~10,000-patient cardiovascular outcomes trial (NCT06383390) remains the last major read-out.
TRIUMPH-1 Phase 3: Retatrutide’s Pivotal Trial Read-Out
Design, reported results and research context for the headline 2026 Phase 3 read-out — 28.3% mean body-weight change at 80 weeks on the 12 mg dose.
Retatrutide Cardiometabolic Markers (ADA 2026)
TRIUMPH-1 Phase 3 data at ADA 2026: retatrutide 12 mg reduced triglycerides 41%, non-HDL cholesterol 24.2% and systolic BP 12.3 mmHg at 80 weeks.
Retatrutide Dysesthesia: TRIUMPH-4 Signal
TRIUMPH-4 (ADA 2026) reported dysesthesia in 20.9% on retatrutide 12 mg vs 0.7% placebo — a class-unique adverse event not seen with other incretin agonists.
Retatrutide Arrhythmia Signal: TRANSCEND-T2D-1
TRANSCEND-T2D-1 (Lancet, ADA 2026) found arrhythmia in 7 of 403 retatrutide participants vs 0 of 134 placebo, plus 3 major cardiovascular events vs 0.
Elecoglipron: Oral GLP-1 Phase 2 (ADA 2026)
SOLSTICE & VISTA Phase 2 data (ADA 2026, The Lancet): AstraZeneca’s oral GLP-1 achieved −1.9% HbA1c and up to 10.5% body-weight change at 26 weeks. Phase 3 planned.
Lilly’s Quintuple Agonist: 5 Receptors (ADA 2026)
Poster 2839-LB (ADA 2026): VRX-0075 targets GLP-1, GIP, glucagon, amylin and calcitonin receptors and outperformed retatrutide for body-weight change in a diet-induced rodent model. Preclinical only.
Research Summary
GLP-1 & Epigenetic Aging: 2026 RCT Evidence
A 2026 Nature Communications RCT reports semaglutide reduced biological age by 3.1–4.9 years across multiple epigenetic clocks in a 32-week randomised trial.
GLP-1 Agonists & Autoimmune CVD Data (2026)
Target trial emulation (JAHA, June 2026; n=26,000): GLP-1 RA use linked to 44% lower mortality and fewer cardiac events in a high-BMI autoimmune disease cohort.
Tirzepatide & Brown Fat: TABFAT Trial (ENDO 2026)
TABFAT trial (ENDO 2026, n=34): tirzepatide raised PET/CT-detected brown adipose tissue activity from 41% to 65% in 24 weeks, independent of body-weight change.
Research Summary
Semaglutide & Biological Aging: Epigenetic Study
Nature Communications RCT (2026): semaglutide reduced biological age by 3–5 years on epigenetic clocks — the first randomised evidence of GLP-1 anti-ageing effects.
Retatrutide vs Aleniglipron (Oral GLP-1)
Structure Therapeutics’ oral aleniglipron reported up to 16.2% body-weight change in Phase 2b (Nature Medicine, 5 Jun 2026); how it compares with retatrutide’s Phase 3 data.
Retatrutide vs Zenagamtide (Amycretin)
Novo’s zenagamtide (amycretin) reported 14.6% body-weight change in a Phase 2b T2D trial (ADA 2026); how it compares with retatrutide’s completed Phase 3 data.
Retatrutide TRIUMPH-2 & TRIUMPH-3 Results
Lilly’s 23 Jul 2026 topline data: up to 20.8% body-weight change in TRIUMPH-2 (T2D population) and 22.6% in TRIUMPH-3 (CVD population); TRIUMPH-3’s MACE analysis was underpowered.
Retatrutide vs Survodutide: Liver-Fat Data
Survodutide’s Phase 3 SYNCHRONIZE-MASLD liver-fat data (Nature Medicine, June 2026) compared with retatrutide’s own Phase 2a MASLD trial results.
Retatrutide vs Berobenatide & Enicepatide
Pfizer’s berobenatide and Roche’s enicepatide posted ADA 2026 Phase 2 data (15.9% and 22.7% body-weight change) — how they compare with retatrutide’s TRIUMPH-1 numbers.
MOTS-c Phase 2a Human Trial (2026)
Hudson Biotech’s Phase 2a trial (NCT07505745) is MOTS-c’s first human efficacy study, testing insulin sensitivity in participants with prediabetes and elevated BMI.
Retatrutide & Cognition: Preclinical Study
A 2026 bioRxiv preprint reports retatrutide preserved memory and cut hippocampal TNF-α in diabetic rats. Preclinical, not yet peer-reviewed.
GLP-1 & Physical Activity: Daily Steps Fell 11% (ENDO 2026)
ENDO 2026 steps study (n=753): daily step counts fell 11% after starting a GLP-1 RA. What the data shows on activity, lean mass and metabolism.
Retatrutide Black-Market Sales: Poison Centre Data (2026)
US poison centres logged a 265% surge in retatrutide exposures as unapproved vials spread to clinics and retail outlets ahead of approval.
Educational Guides
Peptide Research Landscape 2026
TRIUMPH-1, SYNCHRONIZE-1, orforglipron approval, oral semaglutide MHRA, FDA reclassification and the upcoming PCAC hearing — every major 2026 development in one hub.
Guide
What Are Research Peptides? A Plain-English Primer
A simple introduction to what peptides are, how they differ from proteins, and why they are supplied strictly as in vitro research reagents.
Guide
Peptide Storage & Handling in the Lab
How to keep lyophilised and reconstituted research peptides stable - temperature, light, desiccants, and good laboratory practice.
Guide
Bacteriostatic Water Explained
What bacteriostatic water is, how it differs from sterile water, and why it is commonly used to reconstitute peptides in the lab.
Guide
How Peptides Are Tested: HPLC & Mass Spec
A plain-English walk through the two main analytical methods used to confirm a peptide’s purity and identity.
Guide
Peptide Reconstitution Guide
A technical reference for dissolving lyophilised peptides - concentration calculations, sterile handling, and storage guidance.
Guide
How to Read a Certificate of Analysis
What HPLC purity figures mean, how to interpret a CoA, and why mass spectrometry confirmation matters.
Guide
How to Buy Research Peptides in the UK
What to look for in a UK supplier - HPLC documentation, CoA transparency, batch testing, and shipping standards.
Guide
Are Research Peptides Legal in the UK?
The legal status of research peptides under UK law and what “for research use only” means for researchers.
Guide
Most Popular Research Peptides UK (2026)
The most-studied research peptides in the UK in 2026, by research area — tissue repair, incretin/metabolic, neuropeptide, growth-hormone axis and oxidative stress.
Guide
What Makes a Peptide Novel?
A plain-English explainer on sequences, how novelty is checked against databases, and why synthesisability and chain length matter for research peptide design.
Guide
AI Peptide Design, Explained
How an AI model turns a plain-English research target into novel, scored peptide sequences — and where machine-learning fits in an in-vitro research workflow.
Comparisons
SURMOUNT-5: Tirzepatide vs Semaglutide
The first major head-to-head trial of tirzepatide against semaglutide — trial-reported body-weight outcomes, study design and what the data means for incretin research.
Comparison
BPC-157 vs TB-500
Two tissue-repair peptides compared side by side - mechanisms, study models, and the rationale for combining them in research.
Comparison
Semax vs Selank
Two Russian neuropeptides compared - their BDNF and GABA pathway mechanisms and combined research rationale.
Comparison
CJC-1295 vs Tesamorelin
Two GHRH analogues compared - half-life profiles and GH pulse amplitude data from rodent models.
Retatrutide vs Tirzepatide vs Semaglutide
Three incretin receptor agonists compared - receptor targets and the difference between single, dual, and triple agonism.
Is Retatrutide a GLP-1?
Answer-first explainer - why Retatrutide is a GLP-1 / GIP / glucagon triple agonist, with plain-English diagrams.
Comparison
Selank vs DSIP
An anxiolytic neuropeptide compared with a sleep-modulating peptide - distinct mechanisms studied in rodent models.
Comparison
GHK-Cu vs BPC-157
A copper-tripeptide compared with a pentadecapeptide - their differing roles in tissue-remodelling and repair research.
Retatrutide vs Ozempic (Semaglutide)
Triple GLP-1/GIP/glucagon agonism vs single GLP-1 agonism — receptor mechanisms, trial body-weight-change data and research context compared side by side.
Retatrutide vs Wegovy (Semaglutide)
Triple agonism vs single GLP-1 agonism — TRIUMPH-1 vs STEP trial data, receptor mechanisms and where each compound stands in 2026 research.
Glossary & FAQs
Glossary
Research Peptide Glossary (A–Z)
Plain-English definitions of the key scientific and laboratory terms you will meet across our guides and research summaries.
FAQ
Frequently Asked Questions
Answers to common questions about ordering, shipping, documentation, and the research-use-only nature of our compounds.
Research Summaries
Research Summary
BPC-157 Evidence Dispute: 2025–26 Papers
Journals disagree on BPC-157: a 2025 review, a rebuttal on angiogenesis and a 2026 AJSM primer on the limited clinical evidence. A third-party summary of the exchange.
GLP-1 Prescribing Trends, Ages 8–11 (Pediatrics)
A Pediatrics study of 3.5M US records reports GLP-1 prescribing in the 8–11 obesity cohort rose from 0.03% to 9.3% between 2019 and 2026. Data, limits and context.
Research Summary
UCLA 565-Study Peptide Supplement Review
A 2026 AJSM review of 565 studies on BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu found human evidence for efficacy remains lacking.
Retatrutide TRIUMPH Basket-Trial Design
Why Lilly nested sub-studies inside TRIUMPH-1, and how TRIUMPH-2/3/4 extend retatrutide’s Phase 3 programme across metabolic endpoints.
Retatrutide Peptide UK: Research-Grade LY3437943
Retatrutide (LY3437943) availability in the UK as a research-grade peptide — regulatory status, purity standards, and sourcing for researchers.
Survodutide (BI 456906)
A GLP-1/glucagon dual agonist now in Phase 3. SYNCHRONIZE-1 reported 16.6% body-weight change at 46 weeks; LIVERAGE MASH programme ongoing. Updated with 2026 trial data.
Tirzepatide: Preclinical Research Overview
A dual GIP/GLP-1 receptor agonist with SURMOUNT-5 head-to-head data vs semaglutide. Updated with 2026 trial results and the Sandoz generic ANDA filing.
Research Summary
Ipamorelin: Preclinical Research Overview
A selective growth hormone secretagogue (ghrelin-receptor agonist) studied in GH-signalling research.
Retatrutide: Preclinical Research Overview
A GLP-1/GIP/glucagon triple agonist studied in preclinical and early clinical metabolic research.
Retatrutide Reconstitution & Dosing
Bacteriostatic water ratios, mg-per-unit concentration maths, the Phase 2 trial titration schedule and half-life - for research handling.
Retatrutide & Type 2 Diabetes Research
How the GLP-1/GIP/glucagon triple agonist is studied in glycaemic-control and type 2 diabetes research models.
Retatrutide & Sleep Apnea Research
Research context for retatrutide in obstructive sleep apnea and weight-related respiratory studies.
Retatrutide & Osteoarthritis Research
Retatrutide in weight-associated osteoarthritis research — mechanism and preclinical study context.
Retatrutide Side Effects & Tolerability
What the clinical trials reported on retatrutide adverse events and tolerability - gastrointestinal events, dose escalation and the heart-rate signal. Research summary.
Research Summary
BPC-157: Preclinical Research Overview
A synthetic pentadecapeptide studied in angiogenesis, tendon and ligament, and gastrointestinal repair models.
Research Summary
TB-500: Preclinical Research Overview
A thymosin β4 fragment studied for actin binding, cell migration, and angiogenesis in tissue-repair models.
Research Summary
Semax: Preclinical Research Overview
A neuropeptide studied for BDNF and NGF pathway activity in preclinical neuroscience models.
Research Summary
Selank: Preclinical Research Overview
A neuropeptide studied for anxiolytic effects and GABA pathway modulation in rodent models.
Research Summary
CJC-1295: Preclinical Research Overview
A modified GHRH analogue studied for growth-hormone pulse amplitude in preclinical models.
Research Summary
Tesamorelin: Preclinical Research Overview
A GHRH analogue studied for receptor activation and pulsatile GH secretion in rodent models.
Research Summary
GHK-Cu: Preclinical Research Overview
A naturally-occurring copper-tripeptide studied in dermal fibroblast and tissue-remodelling models.
MOTS-C: Preclinical Research Overview
A mitochondrially-encoded peptide studied for AMPK activation and metabolic signalling in rodent models.
Research Summary
NAD+: Preclinical Research Overview
A cellular cofactor studied for energy metabolism and sirtuin pathway activation in animal models.
Research Summary
KPV: Preclinical Research Overview
An alpha-MSH C-terminal tripeptide studied for NF-κB inhibition and mucosal inflammation models.
Research Summary
Melanotan II: Preclinical Research Overview
A melanocortin receptor agonist studied for pigmentation pathway signalling in rodent models.
Research Summary
Glutathione: Preclinical Research Overview
An endogenous tripeptide antioxidant studied for oxidative stress pathways in cellular and animal models.
Research Summary
DSIP: Preclinical Research Overview
A delta sleep-inducing neuropeptide studied for sleep modulation and stress response in rodent models.
Research Summary
Epitalon (Epithalon): Preclinical Research Overview
A synthetic pineal tetrapeptide studied for telomerase activity and melatonin-rhythm regulation in ageing research models.
How Retatrutide Works: Mechanism of Action
A research-focused breakdown of GLP-1, GIP and glucagon receptor pathways activated by LY3437943 — why triple agonism matters for metabolic research.
Retatrutide Clinical Research: All Trial Data
Summary of published retatrutide clinical research: Phase 1 (Lancet 2022), Phase 2 (NEJM 2023) and TRIUMPH Phase 3 data for LY3437943.
Browse the compound catalogue
Every compound page includes a research overview, specification table, and batch testing summary.
